Survival analysis
From Jan. 2009 to June 2018, no patient died from endometrial cancer
with follow-up, 7 (1.8%) patients had recurrence (Table 5). 5-year
overall survival was 100.0% and 5-year progression survival was 98.2%
(7/381). Kaplan-Meier curves showed grade 3 patients were not associated
with shorter overall survival or progression free survival compared with
grade 1&2 group (logrank p>0.05) (Figure 2). In EEC G3
patients at stage I or II, overall survival and progression free
survival analysis showed no distinct difference of two subgroups: The
first was divided into chemotherapy, radiotherapy and chemoradiotherapy
(log rank p>0.05); the second was classified as pelvic LND
(PVLND) and pelvic + para aortic LND (PV+PALND) (log rank
p>0.05) (Figure 3).